NKTR (STOCKS)
Nektar Therapeutics
$81.000000
+3.500000 (+4.52%)
Prev close: $77.500000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Howard W. Robin
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $2,308.24M
- Employees
- 61
- P/E (TTM)
- -7.58
- P/B (TTM)
- 17.58
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
7
Strong Buy
7
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-1.78 | $-2.52 | +0.7436 | +29.47% |
|
Sep 2025 (Q3)
|
$-1.87 | $-2.74 | +0.8682 | +31.71% |
|
Jun 2025 (Q2)
|
$-2.95 | $-3.10 | +0.1457 | +4.71% |
|
Mar 2025 (Q1)
|
$-3.60 | $-2.51 | -1.0864 | -43.22% |
Financial Statements
| Revenues | $55.23M |
| Benefits Costs and Expenses | $219.45M |
| Cost Of Revenue | $0.00 |
| Costs And Expenses | $195.33M |
| Nonoperating Income/Loss | -$15.39M |
| Operating Expenses | $195.33M |
| Depreciation and Amortization | $1.03M |
| Research and Development | $117.33M |
| Other Operating Expenses | $76.98M |
| Operating Income/Loss | -$140.10M |
| Income/Loss Before Equity Method Investments | -$155.49M |
| Income/Loss From Continuing Operations After Tax | -$164.08M |
| Income/Loss From Continuing Operations Before Tax | -$164.21M |
| Income/Loss From Equity Method Investments | -$8.73M |
| Income Tax Expense/Benefit | -$138.00K |
| Income Tax Expense/Benefit, Current | -$202.00K |
| Income Tax Expense/Benefit, Deferred | $64.00K |
| Net Income/Loss | -$164.08M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$164.08M |
| Net Income/Loss Available To Common Stockholders, Basic | -$164.08M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$9.73 |
| Diluted Earnings Per Share | -$9.73 |
| Basic Average Shares | 16,870,930 |
| Diluted Average Shares | 16,870,930 |
| Assets | $280.41M |
| Current Assets | $266.27M |
| Inventory | $0.00 |
| Noncurrent Assets | $14.14M |
| Fixed Assets | $2.06M |
| Other Non-current Assets | $12.08M |
| Liabilities | $190.57M |
| Current Liabilities | $53.54M |
| Accounts Payable | $10.77M |
| Wages | $2.94M |
| Other Current Liabilities | $39.83M |
| Noncurrent Liabilities | $137.04M |
| Equity | $89.83M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $89.83M |
| Liabilities And Equity | $280.41M |
| Net Cash Flow From Operating Activities | -$208.51M |
| Net Cash Flow From Operating Activities, Continuing | -$208.51M |
| Net Cash Flow From Investing Activities | -$1.20M |
| Net Cash Flow From Investing Activities, Continuing | -$1.20M |
| Net Cash Flow From Financing Activities | $180.57M |
| Net Cash Flow From Financing Activities, Continuing | $180.57M |
| Exchange Gains/Losses | $6.00K |
| Net Cash Flow | -$29.14M |
| Net Cash Flow, Continuing | -$29.14M |
| Comprehensive Income/Loss | -$164.12M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$164.12M |
| Other Comprehensive Income/Loss | -$44.00K |